Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Takahiro Kimura, Yu Imai et al.|Japanese Journal of Clinical Oncology|2024Cited by 22
Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration‐sensitive prostate cancer: A multicenter retrospective studyYuki Miura, Chikara Οhyama, Koji Mitsuzuka et al.|The Prostate|2022Cited by 6
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Takahiro Kimura, Hirokazu Kagawa et al.|Prostate International|2024Cited by 6
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate CancerKojiro Tashiro, Takahiro Kimura, Shoji Kimura et al.|Clinical Genitourinary Cancer|2024Cited by 4
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative studyShuhei Hara, Fumihiko Urabe, Kojiro Tashiro et al.|Japanese Journal of Clinical Oncology|2024Cited by 4